GENEVA, October 16, 2026
Alcon (SIX/NYSE: ALC), a global eye care company, announced that the U.S. Food and Drug Administration (FDA) has approved BRYTLY® Redness Reliever Eye Drops, an over-the-counter (OTC) product designed to reduce eye redness and provide a whiter, brighter appearance. According to the company, a single drop begins working in approximately one minute, with redness reduction lasting up to 12 hours. Alcon also reports that BRYTLY provides relief for up to 50% longer than its comparison product, Lumify, based on the studies cited in its announcement. The approval expands Alcon’s consumer eye care portfolio and introduces another option for people seeking temporary relief from visible eye redness. The company expects BRYTLY to become available through major retailers nationwide in the United States and online in the coming months, with additional markets planned for the future.
Single-Drop Formula Targets Long-Lasting Redness Reduction
BRYTLY is designed to reduce visible eye redness while helping eyes appear whiter and brighter throughout the day. Alcon said clinical studies demonstrated significant redness reduction following administration of a single drop, with effects lasting up to 12 hours. The company also highlighted study findings indicating a low risk of rebound redness and tachyphylaxis when the product is used as directed. Rebound redness refers to redness that returns or worsens after the effects of a redness-relief product wear off, while tachyphylaxis describes a reduced response to a treatment following repeated use. According to Alcon, BRYTLY contains no bleaches or dyes and has been shown to be safe and effective when used according to its directions. The company positions the product within the OTC ocular health category, where consumers increasingly seek convenient eye care options that combine clinical evidence with visible results.
FDA Approval Expands Alcon’s Consumer Eye Care Portfolio
The approval adds BRYTLY to Alcon’s range of consumer eye care products and reflects the company’s focus on solutions for everyday ocular health needs. Jonathan Balch, General Manager of Ocular Health & Pharmaceuticals at Alcon, said the approval represents a milestone in bringing the company’s eye care expertise to consumers looking for sustained redness reduction. He noted that eye appearance can be an important consideration in personal care routines and that BRYTLY is intended to provide a convenient option for those seeking whiter-looking eyes. Selina McGee, founder and chief optometrist of Bespoke Vision in Edmond, Oklahoma, also highlighted the relevance of clinically supported redness-relief options for eye care professionals responding to patient questions about eye whiteners. The company’s announcement emphasizes the product’s clinical performance, safety when used as directed and duration of effect. The FDA approval establishes BRYTLY as an additional OTC option for redness relief, while the company’s planned retail rollout will determine when consumers can access it in the market.
Advertisement
Alcon Plans U.S. Retail Launch in Coming Months
Alcon expects BRYTLY to reach major U.S. retailers and online sales channels in the coming months. The company said it also intends to expand availability into additional markets in the future. Founded more than 75 years ago, Alcon describes itself as a global leader in eye care, with surgical and vision care products used by more than 260 million people across over 140 countries and territories each year. Its portfolio addresses a range of eye conditions, including cataracts, glaucoma, retinal diseases and refractive errors. The company employs more than 25,000 associates and works with eye care professionals through product development, partnerships and programs intended to broaden access to eye care. BRYTLY adds a consumer-focused redness-relief product to this portfolio, targeting people seeking a temporary improvement in the appearance of their eyes. Consumers should follow the product’s approved directions and consult an eye care professional if redness persists, worsens or is accompanied by pain or changes in vision.
Source:::Alcon,press release
